Search / Trial NCT06615570

A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Sep 24, 2024

Trial Information

Current as of January 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is testing a new medication called VX-973 to see how safe it is and how it affects the body in healthy participants. The study aims to understand how the drug is absorbed, distributed, and processed by the body, as well as its effects when given in single and multiple doses. If you're between the ages of 18 and 75, weigh more than 50 kg, and do not smoke, you might be eligible to participate.

Participants in the trial will be monitored closely to ensure their safety and well-being while taking the medication. It's important to note that individuals with certain health conditions or recent illnesses may not qualify for the study. If you're interested in participating, you’ll get more details on what to expect, including any necessary screenings and follow-up appointments.

Gender

ALL

Eligibility criteria

  • Key Inclusion Criteria:
  • Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
  • A total body weight of more than (\>) 50 kg
  • Participants of non-childbearing potential
  • Nonsmoker or ex-smoker for at least 3 months before screening
  • Key Exclusion Criteria:
  • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
  • Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
  • Other protocol defined Inclusion/Exclusion criteria may apply.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to the innovation and development of transformative therapies for serious diseases, particularly those with significant unmet medical needs. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in the research and commercialization of treatments for cystic fibrosis and other genetic disorders. Leveraging cutting-edge science and a commitment to patient-centric solutions, Vertex collaborates with healthcare professionals and researchers to advance clinical trials and bring groundbreaking therapies to market, aiming to improve the lives of patients worldwide.

Locations

Salt Lake City, Utah, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0